Table 1 Patient Characteristics.
From: Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
ALK fusion (n = 4) | ROS1 fusion (n = 4) | |
|---|---|---|
Female | 3 (75%) | 2 (50%) |
Age: median (range) | 59 (52–69) years | 54 (47–76) years |
Race: White | 4 (100%) | 4 (100%) |
Performance Status 0 | 3 (75%) | 2 (50%) |
1 | 1 (25%) | 2 (50%) |
Number of Prior Therapies: 1 | 1 (25%) | 0 (0%) |
2 | 2 (50%) | 1 (25%) |
3 | 0 (0%) | 1 (25%) |
>3 | 1 (25%) | 2 (50%) |
Weight loss previous 6 months: < 5% | 4 (100%) | 4 (100%) |
Histologies | ||
Cholangiocarcinoma | 1 | |
Pancreatic adenocarcinoma | 1 | |
Colorectal adenocarcinoma | 2 | 1 |
Ovarian adenocarcinoma | 1 | |
Carcinoma of unknown primary | 1 | |
Leiomyosarcoma | 1 | |
Fusion partners | ||
EML4 | 3 | |
ACTG2 | 1 | |
STRN | 1 | |
GOPC | 4 | |
